Frequency of HCV seropositivity in patients with pruritus
DOI:
https://doi.org/10.66344/jpad.v31i2.1766Abstract
Objective To determine frequency of HCV seropositivity in patients with pruritus.
Methods This study was conducted in Dermatology department, Bolan Medical College/ Sandeman Hospital Quetta. Approval was taken from the institutional ethical review board. The duration of study was six months. A total of 135 patients with pruritus were included in this study. All cases of pruritus having 18 to 60 years of age of either gender were included. Pruritus was diagnosed on the basis of history and physical examination. All patients were screened for the presence of serological evidence of HCV using the 3rd generation ELISA kit for detection of antibodies to human HCV. On the same day a 5ml blood sample was drawn for LFTs. Finally, outcome variable, i.e. frequency of HCV was noted. All the data was entered and analyzed using SPSS version 20.0. Descriptive statistics was used to calculate mean and standard deviation for quantitative variables like age and duration of pruritus. Frequencies with percentages were presented for qualitative variables like gender, abnormal LFTs, family history of HCV positivity, educational status, and outcome was noted. Effect modifiers were controlled through stratification by age, gender, duration of pruritus, family history of HCV seropositivity, educational status and abnormal LFTs to see the effect of these on outcome variables by applying chi-square test taking p-value <0.05 as significant.
Results A total of 135 patients with pruritus were included in this study. Mean age of the patients was 35.84±10.74 years. There were 79 (58.5%) males and 56 (41.5%) females. Family history of HCV positivity was found in 84 (62.2%) patients. There were 57 (42.2%) patients with abnormal LFTs. Frequency of hepatitis C was found in 31 (23%) patients.
Conclusion In this study, frequency of hepatitis C was found in 23% of the patients with pruritus.
References
1. Ford N, Kirby C, Singh K. Chronic hepatitis C treatment outcomes in low-and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:540-50.
doi: 10.2471/BLT.11.097147
2. Hepatitis C An Epidemic for Anyone [online] 2014 [cited 2014 Feb 16].
Available from: URL: http://www.epidemic.org/thefacts/theepidem ic/worldPrevalence/.
3. Cacoub P, Renou C, Rosenthal E. Extrahepatic manifestations associated with hepatitis C virus infection. Medicine (Baltimore). 2000;79:47-56.
4. Muzaffar F, Hussain I, Haroon TS. Hepatitis C: the dermatologic profile. J Pak Assoc Dermatol. 2008;18:171-81.
5. Asim SA, Wahid Z. Cutaneous Manifestations in Hepatitis C virus infection. Pak J Med Sci. 2012;28:891-4.
6. Azfar NA, Zaman T, Rashid T, Jahangir M. Cutaneous manifestations in patients of hepatitis C. J Pak Assoc Dermatol. 2008;18:138-43.
7. Soylu S, Gul U, Kilic A. Cutaneous manifestations in patients positive for antihepatitis C virus antibodies. Acta Derm Venereol. 2007;87:49-53.
8. Halawani MR. Dermatological manifestations of hepatitis C virus infection in Saudi Arabia. Saudi Med J. 2014; 35(6):531-7.
9. Paoletti V, Mammarella A, Basili S. Prevalence and clinical features of skin diseases in chronic HCV infection. A prospective study in 96 patients. Panminerva Med. 2002;44:349-52.
10. Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011; 30:71-86. doi: 10.1016/j.sder.2011.05.002.
11. Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. Dermatol Ther (Heidelb). 2016;6:397-411. doi: 10.1007/s13555-016-0122-9.
12. Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, Gieler U, Lotti T, Lambert J, Maisel P, Streit M, Greaves MW, Carmichael AJ, Tschachler E, Ring J, Ständer S. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92:563-81.
13. Fuhrmann V, Drolz A, Trauner M. Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus. Liver Int. 2011;31:31-3.
doi: 10.1111/j.1478-3231.2011.02584.x.
14. Ghosh S, Duseja A, Dhiman RK, Chawla YK. Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C. Dig Dis Sci. 2012;57:820-821.
doi: 10.1007/s10620-011-1914-5
15. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360:1839-50.
doi: 10.1056/NEJMoa0807650.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Sehrish Ghani, Sara Inayat, Zaib, Anila Panezai, Saif Ullah, Mehvish Afridi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
